Unknown

Dataset Information

Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.


ABSTRACT: Obesity is a major correlate of cardiovascular disease. Weight loss improves cardiovascular risk factors and has the potential to improve outcomes. Two drugs, phentermine plus topiramate and lorcaserin, have recently been approved by the US Food and Drug Administration for the indication of obesity; a third, bupropion plus naltrexone, is under consideration for approval. In clinical trials, these drugs cause weight loss and improve glucose tolerance, lipid profile, and, with the exception of bupropion plus naltrexone, blood pressure. However, their effect on cardiovascular outcomes is unknown. In defining appropriate roles for these drugs in preventive cardiology, it is important to remember the checkered history of drugs for obesity. New weight-loss drugs share the serotonergic and sympat

SUBMITTER: Cunningham JW 

PROVIDER: S-EPMC6649490 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature